anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ETHNOPHARMACOLOGICAL RELEVANCE: Sepsis-induced lung injury is closely associated with it remarkable morbidity and mortality. Shenhuangdan (SHD) decoction, a traditional Chinese medicine prescription, has been clinically proven to be an effective treatment for sepsis. However, the mechanism of SHD decoction in treating sepsis remains unclear.
AIM OF THE STUDY: This study aimed to evaluate the therapeutic effect of SHD decoction on sepsis-induced lung injury and its underlying mechanism.
MATERIALS AND METHODS: In this study, we established a mouse model of sepsis by cecum ligation and puncture (CLP) surgery. Firstly, seven-day survival analysis and histological staining of lung tissue were used to evaluate the therapeutic effect of SHD decoction on lung injury in septic mice. Multifactor microarray was used to detect cytokine expression changes in serum and bronchoalveolar lavage fluid (BALF). Subsequently, the main components in medicated serum of SHD decoction were inspected by Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). The material basis of SHD decoction and potential interaction mechanisms were analysed by systemic pharmacology. To confirm the reliability of network pharmacology for predicting outcomes, we used molecular docking techniques to identify interactions between the core components and targets of SHD. Finally, TUNEL staining, immunofluorescence and western blotting were used to explore the mechanism of SHD decoction through the inhibition of GSDMD-mediated pyroptosis in septic mice.
RESULTS: SHD was found to be effective in reducing the mortality and alleviating lung pathological damage in septic mice. Multifactor microarray results showed that SHD can reduce the expression of inflammation factors (IL-18, IL-1β, IL-5, IL-6 and TNF-α) in serum and BALF of septic mice. There were 22 major blood-entry components detected by UPLC-MS/MS. Then, combined with the network pharmacological analysis, it is evident that the main components of SHD for sepsis are Renshen-ginsenoside Rh2, Danshen-tanshinone IIA and Dahuang-rhein. The main targets were IL-1β and caspase-1, which were related to GSDMD-mediated pyroptosis signalling pathway. Molecular docking exhibited that Renshen-ginsenoside Rh2, Danshen-tanshinone IIA and Dahuang-rhein can closely bind to GSDMD, IL-1β and caspase-1. In addition, TUNEL staining and immunohistochemistry demonstrated that SHD alleviated the expression of GSDMD protein. The western blotting showed that SHD significantly inhibited the protein expression levels of NLRP3, GSDMD, GSDMD-N, cleved caspase-1, caspase-1 and ASC in lung tissue.
CONCLUSIONS: Our study revealed that SHD improves CLP-induced lung injury by blocking the GSDMD-mediated pyroptosis signalling pathway in septic mice. This study provides evidence to support that SHD had a potential therapeutic effect on sepsis.
The present invention relates to thiol/disulphide azo quinolinium compounds for dyeing keratin fibres. The invention relates to a dye composition comprising a particular thiol/disulphide azo quinolinium chromophore-containing thiol or disulphide dye, and to a process for dyeing keratin fibres such as the hair, using said composition. It similarly relates to novel particular thiol/disulphide azo quinolinium chromophore-containing dyes and to the uses thereof in dyeing keratin fibres. The dyeing process according to the invention makes it possible to dye keratin fibres without damaging them, in a manner which is particularly persistent with respect to shampooing operations and common attacks. Moreover, the novel dyes according to the invention extend the colour range to violets and blues. This process also makes it possible to dye bleached keratin fibres in a strong and chromatic manner.
The present invention relates to a novel assay or screen for identifying compounds with potential therapeutic value for the treatment of protein trafficking diseases such as Cystic Fibrosis (CF) and nephrogenic diabetes insipidus (NDI). The usual approach involves expressing the mutant form of the gene in cells and assaying function in a multiwell format when cells are exposed to libraries of compounds. Although such functional assays are useful, they do not directly test the ability of a compound to correct defective trafficking of the protein. To address this a novel corrector screening assay for CF has been developed in which the appearance of the mutant protein at the cell surface is measured as the assay output. This assay was used to screen more than 3100 compounds. This novel screening approach to protein trafficking diseases is robust and general, and may enable the selection of molecules that can be translated rapidly to a clinical setting.
The present invention relates to a kidney-invigorating capsule which is a pure traditional Chinese medicinal preparation for treating acute and chronic glomerular nephritis, henoch-schonlein purpura nephritis, lupus nephritis, chronic pyelonephritis, nephrotic syndrome, uremia and prostatitis. The kidney-invigorating capsule is prepared from the traditional Chinese medicines of Chinese caterpillar fungus, common aucklandia root, rhubarb, cape jasmine kernel, bezoar, water plantain, red sage root, dodder seed, ginseng fruit, twotoothed achyranthes root, bloody velvet deer antler, ginseng, etc. Nephropathy is caused by toxin accumulation in a body. The capsule originally provides the basic therapeutical principles of detoxicating toxin and expelling toxin, and can regulate the endocrine system, restoring glomerulus, enhancing tubular reabsorption function and activating the immune system of a human body by the treatment methods of promoting blood circulation to disperse blood clots, promoting qi circulation to induce diuresis, eliminating swelling, nourishing kidney yin, invigorating kidney yang, purifying blood, etc. so as to achieve the effect of treatment of both manifestation and casual causes of nephropathy. Compared with the similar medicines, the kidney-invigorating capsule has the characteristics of quick effect, reliable therapeutic effect and no toxic or side effect.
Behavioural and physiological resistance are key to slowing epidemic spread. We explore the evolutionary and epidemic consequences of their different costs for the evolution of tolerance that trades off with resistance. Behavioural resistance affects social cohesion, with associated group-level costs, while the cost of physiological resistance accrues only to the individual. Further, resistance, and the associated reduction in transmission, benefit susceptible hosts directly, whereas infected hosts only benefit indirectly, by reducing transmission to kin. We therefore model the coevolution of transmission-reducing resistance expressed in susceptible hosts with resistance expressed in infected hosts, as a function of kin association, and analyse the effect on population-level outcomes. Using parameter values for guppies, Poecilia reticulata, and their gyrodactylid parasites, we find that: (1) either susceptible or infected hosts should invest heavily in resistance, but not both; (2) kin association drives investment in physiological resistance more strongly than in behavioural resistance; and (3) even weak levels of kin association can favour altruistic infected hosts that invest heavily in resistance (versus selfish tolerance), eliminating parasites. Overall, our finding that weak kin association affects the coevolution of infected and susceptible investment in both behavioural and physiological resistance suggests that kin selection may affect disease dynamics across systems.
Obsessive-compulsive disorder(OCD) is one of relatively common mental disorders with a prevalence of 1.63% in China. OCD usually begins in adolescence or young adulthood , it will become a chronic disabling disease, if it is not treated in timeand.OCD can be so severe that it can seriously impact on some or all areas of a person's life, bring huge economic burden. At present, there is only one article on the cost of OCD in the United States in the 1990s, and this part of the data in China is blank.A cross-sectional study recruited 600 patients with OCD from 13 hospitals in eastern, western, southern, and northern China. A structured questionnaire was used for face-to-face interviewing to collect costs related to OCD. The direct costs for each patient and indirect costs ffor each patient and their caregivers were calculated . The human capital method is used to calculate indirect costs. Through weighting, the cost of OCD in China is estimated from a social perspective using a bottom-up methodology.
Patients receive niraparib PO QD on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Following completion of treatment, patients then undergo standard of care surgery.
<P>PROBLEM TO BE SOLVED: To provide a sheet brush for the hair capable of improving convenience as a brush for trimming or caring for the hair through facilitating combing the hair with the help of projections thereon.  <P>SOLUTION: This sheet brush 10 for the hair is such one that one side of a substrate sheet 11 is provided with the plurality of projections 12. Each of the projections 12 has an S-shaped flat cross section, conically projecting with the sectional area reduced upward, and the projections 12 are distributed on the one side of the substrate sheet 11 with the longitudinal directions X of the respective S-shaped cross sections parallel to each other. The substrate sheet 11 is made of nonwoven fabric, the projections being provided by projecting part of the substrate sheet 11. This sheet brush 10 is to be used after being impregnated with any of various hair cosmetics including a deodorant base, deodorizing base, water-absorbing base, antimicrobial agent and ultraviolet light absorber.  <P>COPYRIGHT: (C)2003,JPO
The invention relates to biomedical engineering and tumor immunology. A method provided by the invention is that: patient autologous peripheral blood is collected; peripheral blood mononuclear cells are subjected to in-vitro induction by using MEK as a costimulatory factor and cytokine, such that novel CIK and DC killer cells are prepared, and a problem of insufficient patient DC cell in-vitro culture number is solved; DC is combined with a tumor antigen, such that APDC tumor vaccine is prepared. The tumor vaccine has both treatment effect and food prevention effect. Tumor antigen peptide is prepared, wherein a surgically excised tumor such as a tumor of liver cancer, lung cancer, prostate cancer, breast cancer, colon cancer, and the like is subjected to mRNA extraction; the mRNA is irradiated by using cobalt 60, such that carcinogenicity is removed, and good immunogenicity is maintained. Cell antigen is prepared, wherein tumor passed cells are adopted, and mRNA is extracted; the mRNA is used for transfecting tumor antigen; cobalt 60 irradiation is carried out; and the antigen is presented to a killer cell through a fusion method, such that a specific tumor vaccine is prepared. The vaccine has the characteristics of good killing effect, high safety, and no toxic or side effect.
PURPOSE:To obtain high specificity and sensitivity by binding chemically or adsorbing physically an antigen to latex particles having a specific grain size and removing the excess amt. of the agtigen then bringing the corresponding antiserum or refined antibody into reaction therewith. CONSTITUTION:Latex is synthetic polymer latex particles of polystyrene, polybutadiene or polystyrene, etc. having a functional group on the surface and the surface thereof may be treated with a nonionic surfactant, etc. The grain size of the latex particles is 0.01-10mu, more preferably 0.1-1.0mu and has preferably a narrow width of the grain size distribution to improve the reproducibility of the result of measurement. The conceivable antigen to be bound chemically or adsorbed physically to the latex particles is the antigen originating in animals such as guinea pig, rabbit, goat, etc. and the antigen stable to heat, acids and alkalis is more preferable as far as said material is recognizable as the antigen. The antibody to be made correspondent to the antigen adsorbed to the latex particles is obtd. from animals such as guinea pig, rabbit, goat, etc. which can produce the antibody.
Ataxia telangiectasia is an autosomal recessive multisystem disorder which is characterized by a progressive ataxia, conjunctival telangiectasia, a humoral and cellular immunodeficiency, an increased radiosensitivity and an increased risk for cancer (Boder E, Pediatrics, 1957). Most patients die in their 2nd or 3rd decade of life due to a respiratory failure caused by progressive (interstitial) lung disease or due to malignancies (Schroeder SA, Pediatr Pulmonol, 2010). In 1995 the sequence of the mutated AT gene (ATM) on chromosome 11q22-23 was identified. Main problems besides the progressive neurodegeneration are recurrent infections of upper and lower respiratory tract and a growth retardation and malnutrition. These problems are caused by a mutation in the ATM gene on chromosome 11, which encodes for a protein with several key functions in control of cell cycle and apoptosis (Savitsky K et al., Hum Mol Gen, 1995). Several works already showed that patients with AT have a variable immunodeficiency which is characterized by low lymphocyte counts, a lack of Immunoglobulin A (IgA), Immunoglobulin G subclasses (IgG2 and 4) and specific pneumococcal antibodies (Schubert R, Clin Exp Immunol, 2002). The course of disease is dependent on the AT mutation respectively the residual kinase activity of ATM which is found in about 10% of A-T patients. These patients are described as 'variant ATs´ and have a better prognosis regarding immunodeficiency, susceptibility to infections and a possible growth retardation and malnutrition (Verhagen M, Hum Mutat, 2012). Despite the evidence for a humoral immunodeficiency a treatment with polyvalent immunoglobulins (IgG) is not practiced in generally. In the 'Clinical Workshop on Ataxia Teleangiectasia´, that took place in Frankfurt in January 2011, the investigators found out that the percentage of A-T patient, that are supplemented with immunoglobulins was only 10% to 60% depending on the different clinical centres.The Goethe University Childrens Hospital in Frankfurt, the biggest A-T centre in Germany, takes care for more than 40 A-T patients. At the moment about 15% of these patients are treated with immunoglobulins. Some observations show that the progress of the chronic lung disease cannot be prevented the usage of immunoglobulins. By now it´s not clear in what way patients suffer from an increased susceptibility to infections and if a substitution with immunoglobulins is needed. The aim of this trial is to investigate the incidence, intensity and duration of infections in patients with A-T compared to age matched healthy controls.
The present invention discloses an animal feed additive capable of preventing and treating a livestock foot-and-mouth disease. In the animal feed additive, traditional Chinese medicines and mineral resources are used as main raw materials. The animal feed additive is mainly prepared from the water extract and the ethanol extract of the raw materials in the following portions by weight and the mineral substances as raw materials in the following portions by weight: 5 to 20 portions of Herba Schizonepetae, 5 to 10 portions of bupleurum root, 5 to 10 portions of radix platycodi, 5 to 10 portions of Herba Andrographis, 5 to 20 portions of climbing groundsel, 5 to 10 portions of many-flowered glory-bower, 10 to 50 portions of zeolite powder and 10 to 50 portions of melanterite powder. The present invention also discloses a preparation method of the additive. The present invention can effectively prevent the livestock foot-and-mouth disease from occurring, treat the livestock foot-and-mouth disease and significantly reduce the disease incidence rate of the livestock foot-and-mouth disease. The present invention has the advantages of obvious effects and convenient use.
1,203,650. Quinazolinones. SANDOZ Ltd. 16 Nov., 1967 [4 Oct., 1967], No. 52253/67. Addition to 1,195,066. Heading C2C. Novel compounds of Formula Ia in which R is H, F, Cl or Br; X is a C 3-5  branched alkyl radical, the branching occurring in the carbon atom attached to the ring nitrogen atom other than a tertiary such alkyl radical in which the tertiary C is directly attached to the N of the quinazolinone ring; R 2  is a phenyl radical optionally substituted by Y and Y 1 , Y being F, Cl, Br,-OH, C 1-4  alkyl or alkoxy or -CF 3  and Y 1  being H, F, Cl, Br, OH, C 1-4  alkyl or alkoxy; are prepared by reacting a compound of Formula IIa with a C 1-5  alkyl carbamate in the presence of a Lewis acid catalyst at a temperature of at least 140 C.
The inflammatory microenvironment and inferior chondrogenesis are major symptoms after cartilage defect. Although various modifications strategies associated with hydrogels exhibit remarkable capacity of pro-cartilage regeneration, the adverse effect by prolonging inflammation is still formidable to hamper potential biomedical applications of different hydrogel implants. Herein, inspired by the repair microenvironment of articular cartilage defects, an injectable, immunomodulatory, and chondrogenic L-MNS-CMDA hydrogel is prepared through grafting vinyl and catechol groups to chitosan macromolecules using amide reaction, then further loading MnO2 nanosheets (MNS). The double crosslinking of photopolymerization and catechol oxidative polymerization endows L-MNS-CMDA hydrogel with preferable mechanical property, affording a suitable mechanical support for cartilage defect repair. Additionally, the robust tissue adhesion capability stemming from catechol groups guarantees the long-term retention of the hydrogel in the defect site. Meanwhile, L-MNS-CMDA hydrogel decomposes exogenous and intracellular H2O2 into O2 and H2O, to effectively alleviate cellular oxidative stress caused by long-term hypoxia. Under the synergies of catechol groups and MNS, L-MNS-CMDA hydrogel not only inhibits macrophages polarizing into M1 phenotype, but encourages them turn into M2 phenotype, thereby, reconstructing an immunization friendly microenvironment to ultimately enhance cartilage regeneration. Predictably, the hydrogel markedly induces rat bone marrow mesenchymal stem cells differentiating into chondrocytes by expressing abundant glycosaminoglycan and type II collagen. A cartilage defect model of rat knee joint indicates that L-MNS-CMDA hydrogel visually regulate the early inflammatory response of post-implantation, and facilitate cartilage regeneration and recovery of joint function after 12 weeks of post-implantation. All in all, this multifunctional L-MNS-CMDA hydrogel exhibits superior immunomodulatory and chondrogenic properties, holding immense clinical potential in the treatment of cartilage defects.
Patients will be treated with cabozantinib 60 mg daily administered orally continuously for 28-day cycles. Tumor assessments will be performed every 8 weeks until documented disease progression by RECIST criteria or drug intolerance.
Facial skin redness can be an indicator of skin inflammation, however the physiological connection between facial redness and inflammatory status, as well as its role in age-related skin changes, remains poorly understood. This study aims to investigate the association between the pattern of facial skin redness and biological inflammatory status, as well as age-related changes occurring in the skin. Four studies were conducted recruiting healthy Northern Asian females. Disordered spatial patterns of facial skin redness signals were assessed using image analysis, i.e., the a* gradient algorithm, which quantifies the disordered shape and pattern of localized redness signals on facial skin. This redness pattern was compared with (1) inflammatory protein markers (IL-1Ra/ IL-1α and IL-8) measured from stripped corneocyte samples, (2) gene expression profiles obtained through transcriptome analysis using skin biopsy samples, and (3) the distribution pattern of blood vessel measured using a photoacoustic microscope. The association between the skin redness pattern and current and future ageing-related skin changes was examined through a longitudinal study tracking the same subjects for 10 years. A significant correlation was observed between the a* gradient and the levels of inflammatory cytokines (IL-1Ra/IL-1α and IL-8). Transcriptome analysis revealed upregulation of genes related to acute inflammation, chronic inflammation, cellular senescence, and angiogenesis in subjects with higher a* gradients. The high a* gradient group exhibited an extension of blood vessel diameter and increased blood vessel density, while the medium a* gradient group only exhibited blood vessel extension. Lastly, the 10-year longitudinal study demonstrated that the a* gradient was associated with current and future skin ageing-related attributes, such as increased skin texture and wrinkle formation. The spatial pattern of localized redness on the skin reflects the biological inflammatory status, and this inflammatory condition helps predict current and future age-related skin changes.
Apply Diclona Patch to intact skin to cover the most painful area. Clean and dry the affected area. Apply product directly to your skin, up to 2 times daily. Diclona Patch should not be worn for longer than 12 hours per application. Clothing may be worn over the area of application. Patches may be cut into smaller sizes with scissors prior to removal of the protective film.

If irritation or a burning sensation occurs during application, wash the product off your skin and do not reapply until the irritation subsides.

When Diclona Patch is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.
Patient will be accrued and started on dose 1 level of PAC-1 (500 mg). If no DLT is observed in first cycle of therapy (28 days), dose of PAC-1 will be escalated to 625 mg in second cycle of therapy for the same patient. If patient remains on study and has no dose limiting toxicities, then in third cycle, dose will be escalated to 750 mg and continue in following cycles, if no dose adjustment is needed because of toxicities. Nivolumab will be administered by IV infusion at a dose of 480 mg.